Bacteroides in colonic mucosa-associated microbiota affects the development of minimal hepatic encephalopathy in patients with cirrhosis.


Journal

Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 13 02 2019
accepted: 17 06 2019
pubmed: 11 7 2019
medline: 28 1 2020
entrez: 11 7 2019
Statut: ppublish

Résumé

Gut microbiota has been associated with liver cirrhosis and, possibly, hepatic encephalopathy. However, only a few studies have examined the link between mucosa-associated microbiota (MAM) and minimal hepatic encephalopathy (MHE). Our aim was to investigate this relationship. Twenty-four patients with cirrhosis underwent colon biopsies at our institution, between January 2014 and April 2015. Patterns of microbial colonization were examined using 16S rRNA gene sequences. MHE was diagnosed using the Neuropsychological Test. Ten (41.7%) of the 24 patients were diagnosed as having MHE. There was no significant difference in the diversity of gut microbiota by sampling locations between those with and without MHE. However, the diversity of the gut microbiota and the proportion of the genus Bacteroides decreased as a function of declining liver function. We divided patients into those with the highest proportion of the genus Bacteroides (Bacteroides-dominant group; n = 9) and into a Bacteroides non-dominant group (n = 15). In the Bacteroides-dominant group, only 1 patient (11.1%) was diagnosed as having MHE, with the incidence rate of MHE being significantly lower in the Bacteroides-dominant group than in the non-dominant group (p = 0.019). The Child-Pugh score (p = 0.05) and use of proton-pump inhibitors (p = 0.015) were negatively correlated to the proportion of Bacteroides. Furthermore, the proportion of the family Clostridiaceae was significantly higher in the Bacteroides-dominant group than in the non-dominant group (p = 0.078). The decrease in microbial diversity and genus Bacteroides in MAM is a risk factor for MHE in patients with liver cirrhosis.

Sections du résumé

BACKGROUND/PURPOSE OBJECTIVE
Gut microbiota has been associated with liver cirrhosis and, possibly, hepatic encephalopathy. However, only a few studies have examined the link between mucosa-associated microbiota (MAM) and minimal hepatic encephalopathy (MHE). Our aim was to investigate this relationship.
METHODS METHODS
Twenty-four patients with cirrhosis underwent colon biopsies at our institution, between January 2014 and April 2015. Patterns of microbial colonization were examined using 16S rRNA gene sequences. MHE was diagnosed using the Neuropsychological Test.
RESULTS RESULTS
Ten (41.7%) of the 24 patients were diagnosed as having MHE. There was no significant difference in the diversity of gut microbiota by sampling locations between those with and without MHE. However, the diversity of the gut microbiota and the proportion of the genus Bacteroides decreased as a function of declining liver function. We divided patients into those with the highest proportion of the genus Bacteroides (Bacteroides-dominant group; n = 9) and into a Bacteroides non-dominant group (n = 15). In the Bacteroides-dominant group, only 1 patient (11.1%) was diagnosed as having MHE, with the incidence rate of MHE being significantly lower in the Bacteroides-dominant group than in the non-dominant group (p = 0.019). The Child-Pugh score (p = 0.05) and use of proton-pump inhibitors (p = 0.015) were negatively correlated to the proportion of Bacteroides. Furthermore, the proportion of the family Clostridiaceae was significantly higher in the Bacteroides-dominant group than in the non-dominant group (p = 0.078).
CONCLUSIONS CONCLUSIONS
The decrease in microbial diversity and genus Bacteroides in MAM is a risk factor for MHE in patients with liver cirrhosis.

Identifiants

pubmed: 31290070
doi: 10.1007/s12072-019-09963-2
pii: 10.1007/s12072-019-09963-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

482-489

Références

Hepatology. 2007 Mar;45(3):549-59
pubmed: 17326150
Cytotechnology. 2007 Dec;55(2-3):89-101
pubmed: 19002998
N Engl J Med. 2010 Mar 25;362(12):1071-81
pubmed: 20335583
J Hepatol. 2010 Nov;53(5):849-55
pubmed: 20675008
Hepatology. 2012 Apr;55(4):1154-63
pubmed: 22095436
FEMS Microbiol Ecol. 2012 Jun;80(3):624-36
pubmed: 22324305
Am J Physiol Gastrointest Liver Physiol. 2012 Sep 15;303(6):G675-85
pubmed: 22821944
Hepatol Res. 2013 May;43(5):452-8
pubmed: 22994429
Nature. 2012 Oct 4;490(7418):55-60
pubmed: 23023125
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
Gut. 2013 Dec;62(12):1787-94
pubmed: 23197411
Nature. 2013 Aug 8;500(7461):232-6
pubmed: 23842501
Nat Rev Microbiol. 2013 Sep;11(9):639-47
pubmed: 23912213
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
J Hepatol. 2014 May;60(5):940-7
pubmed: 24374295
Gut Microbes. 2014 May-Jun;5(3):397-403
pubmed: 24690956
J Hepatol. 2015 Feb;62(2):437-47
pubmed: 25218789
Clin Gastroenterol Hepatol. 2015 Jul;13(7):1346-52
pubmed: 25572976
Hepatology. 2016 Jan;63(1):339-40
pubmed: 26264779
Aliment Pharmacol Ther. 2015 Nov;42(10):1211-21
pubmed: 26376728
Gut. 2016 May;65(5):749-56
pubmed: 26719299
Cell Host Microbe. 2016 Feb 10;19(2):227-39
pubmed: 26867181
Hepatology. 2016 Oct;64(4):1232-48
pubmed: 27339732
Biomed Rep. 2016 Aug;5(2):193-198
pubmed: 27446540
Gastroenterology. 2017 Jan;152(1):134-141
pubmed: 27639806
Ann Gastroenterol. 2017;30(5):486-497
pubmed: 28845103
Hepatol Int. 2019 Mar;13(2):234-244
pubmed: 30737678
J Med Microbiol. 1980 May;13(2):177-91
pubmed: 7381915

Auteurs

Masafumi Haraguchi (M)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Satoshi Miuma (S)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan. miuma1002@nagasaki-u.ac.jp.

Hiroshi Masumoto (H)

Biomedical Research Support Center, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki, Nagasaki, 852-8523, Japan.

Tatsuki Ichikawa (T)

Department of Gastroenterology, Nagasaki Harbor Medical Center City Hospital, 6-39, Shinchi, Nagasaki, Nagasaki, 850-8555, Japan.

Yasuko Kanda (Y)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Ryu Sasaki (R)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Masanori Fukushima (M)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Hisamitsu Miyaaki (H)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Naota Taura (N)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Kazuhiko Nakao (K)

Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, Nagasaki, 852-8501, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH